Point of Care (POC) Molecular Diagnostics - Global Strategic Business Report

The global market for Point of Care (POC) Molecular Diagnostics is estimated at US$3.7 Billion in 2023 and is projected to reach US$8.8 Billion by 2030, growing at a CAGR of 13.1% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

The growth in the POC molecular diagnostics market is driven by several factors. Technological advancements that enhance the accuracy, speed, and user-friendliness of POC devices are major contributors to market expansion. The ongoing development of multiplexing capabilities, where multiple tests are conducted at the same time on the same device, also significantly boosts the utility and attractiveness of POC diagnostics. Furthermore, the increasing global burden of infectious diseases and the rising demand for rapid diagnostic methods in pandemic management highlight the critical role of POC testing. Economic factors, including cost savings associated with reduced hospital stays and less reliance on centralized laboratory facilities, encourage the adoption of POC diagnostics across various healthcare settings. Consumer behavior, particularly the growing expectation for immediate healthcare delivery and the rising awareness of personalized medicine, further propels the demand for these innovative diagnostic solutions.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the PCR-based POC Molecular Diagnostics segment, which is expected to reach US$5.7 Billion by 2030 with a CAGR of a 14.0%. The Genetic Sequencing-based POC Molecular Diagnostics segment is also set to grow at 10.5% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $1.5 Billion in 2023, and China, forecasted to grow at an impressive 15.9% CAGR to reach $1.0 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Point of Care (POC) Molecular Diagnostics Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Point of Care (POC) Molecular Diagnostics Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Point of Care (POC) Molecular Diagnostics Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of major players such as Bayer AG, Danaher Corporation, DiaSorin SpA, and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 64 Featured):

• Bayer AG
• Danaher Corporation
• DiaSorin SpA
• Biocartis NV
• Maxim Biomedical, Inc.
• AccuBioTech Co., Ltd.
• Abacus Diagnostica Oy
• genedrive plc
• Molbio Diagnostics Pvt. Ltd.
• Mesa Biotech, Inc.
• Binx Health
• Credo Diagnostics Biomedical Pte. Ltd
• Genestat Molecular Diagnostics, LLC
• Alveo Technologies
• ADOR Diagnostics